Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Landscape of Genetic Mutations in Appendiceal Cancers.
Constantin M et al.
Cancers, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors.
Min BJ et al.
Cancers, 2021
KRAS: From undruggable to a druggable Cancer Target.
Uprety D et al.
Cancer Treatment Reviews, 2020
Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1.
Xie J et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach.
Manca A et al.
Journal of Translational Medicine, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Newell F et al.
Nature Communications, 2019
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Oliveira DM et al.
Oncotarget, 2018
Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2018
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Kato S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
Sun QY et al.
Leukemia, 2017
Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV et al.
Genome Medicine, 2016
Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types.
Dias-Santagata D et al.
American Journal of Clinical Pathology, 2016
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.
Rennert H et al.
Npj Genomic Medicine, 2016
Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.
Ikeda Y et al.
Oncology Reports, 2013
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
Krakstad C et al.
Plos One, 2012
Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.
Gast A et al.
Genes, Chromosomes & Cancer, 2010
Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.
Jovanovic B et al.
The Journal of Investigative Dermatology, 2008
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
Banerji U et al.
Molecular Cancer Therapeutics, 2008